The Trump administration is distancing itself from US House Speaker Nancy Pelosi's proposed legislation to lower drug prices, and instead supporting a bipartisan plan in the Senate put forward by Senators Chuck Grassley and Ron Wyden, reported The Hill.
"Lines of communication remain open with the Speaker's office, but the Grassley-Wyden proposal is the most likely solution that could advance on a bipartisan basis and achieve the President's priority of lowering drug prices," said White House spokesman Judd Deere.
Pelosi's legislation would allow the secretary of Health and Human Services to negotiate lower prices for up to 250 drugs per year, with the lower prices also applied to private insurers.
The Grassley-Wyden bill does not include negotiation, and it is centered on lowering drug prices in Medicare, in contrast to Pelosi's bill, which would also lower prices for people with private insurance.
The Grassley-Wyden bill does require drugmakers to pay money back to Medicare if their prices rise faster than inflation, though many Republicans have objected on that point and the White House has expressed openness to taking it out.
To read more NewsPoints articles, click here.